Latest News
Category: News
News,
Telix today announces two abstract presentations featuring the Company’s therapeutic radiopharmaceutical programs at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, Illinois from May 31 – June 4,...
Read more
Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”)...
Read more
Telix today announces the successful completion of CUPID, a first-in-human Phase I dose escalation study of TLX592 in patients with advanced prostate...
Read more
Telix today announces three abstract presentations featuring the Company’s theranostic programs at the British Nuclear Medicine Society (BNMS) Annual Spring Meeting being held in Belfast, Northern Ireland this week....
Read more
News,
Telix today announces an agreement with Cardinal Health Nuclear & Precision Health Solutions (a subsidiary of Cardinal Health, Inc.) for the global clinical supply of actinium-225 (Ac-225), a therapeutic radioisotope...
Read more
Telix today announces the completion of the acquisition of QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United States (U.S.) based company...
Read more
Telix today announces that the first patient has been dosed in its named patient program in Austria for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®). TLX250-CDx is the Company’s investigational non-invasive carbonic anhydrase IX...
Read more
Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs in urology at the American Urological Association (AUA) Annual Meeting being held in San Antonio from May...
Read more
Telix today announces that the first patient has been dosed in a Special Access Scheme (SAS) in Australia for TLX250-CDx (89Zr-DFO-girentuximab, Zircaix®) positron emission tomography (PET) imaging in clear cell...
Read more
Telix today announces five oral abstract presentations featuring the Company’s late-stage theranostic programs at the 54th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM...
Read more